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Hemophilia A mice with pre-existing inhibitory antibodies against
factor VIII (FVIII) were treated with single agents, AMD3100 and
GCS-F, respectively. Inhibitor titers in treated mice and control
HemA inhibitors mice were followed over time. Total B cells and
plasma cells (PCs) were characterized by ﬂow cytometry. HemA
inhibitor mice were then treated with a combination regimen of
IL-2/IL-2mAb complexes plus rapamycin and AMD3100. Finally,
HemA inhibitor mice were treated with a new combination
therapy using include IL-2/IL-2mAb complexes þ Anti-
CD20þAMD3100þG-CSF. The timeline of combination therapy
was illustrated. Inhibitor titers following treatment in FVIII plasmid
or protein induced inhibitor mice were evaluated overtime. A
representative ﬁgure and gating strategies to characterize the
subsets of Treg cells and B cells are presented. Please see http://dx.
doi.org/10.1016/j.cellimm.2016.01.005 [1] for interpretation and
discussion of these data and results.
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featuresGroups of animals were treated with plasmid mediated gene therapy or protein
replacement therapy followed by immunomodulationata source
locationSeattle, USAata accessibility Data is with this articleDValue of the data This is the ﬁrst attempt to use stem cell mobilizing agents to modulate pre-existing anti-FVIII
antibodies.
 Using combination therapy with Treg expansion agents IL-2/IL-2mAb complexes and rapamycin
illustrates the importance of Treg cells not only in prevention of anti-FVIII antibody production but
also in modulating pre-existing antibody responses.
 Detailed analysis of changes in subsets of T and B cells can help elucidate the mechanisms of these
immunomodulation agents with single or combination treatment.1. Data
Hemophilia A (HemA) mice were treated with either FVIII plasmid or protein to induce production of
pre-existing inhibitory antibodies. These HemA inhibitor mice were then treated with either single
agent or combination treatment. Immune responses against FVIII and FVIII activities were followed over
time. Subsets of B and T cells were analyzed using ﬂow cytometry. First, HemA inhibitor mice were
treated with a single cycle (200 μg/mouse/day for 10 days) of AMD3100. HemA inhibitor mice were
used as controls. Antibody titers in treated and control mice were shown in Fig. 1A and B. Staining
results of total B and CXCR4þ plasma cells (PCs) were shown in Fig. 1C and D. Next, we explored the
single cycle treatment of G-CSF (250 μg/kg/day for 5-days) in HemA inhibitor mice. Antibody titers and
staining results of total B and PCs are shown in Fig. 2. Subsequently, we treated HemA mice with a
combination regimen (IL-2/IL-2mAb complexesþrapamycinþAMD3100) for 4 weeks. Antibody titers in
treated and control mice were shown in Fig. 3A and B. Peripheral blood mononuclear cells (PBMCs) in
HemA mice were collected on weeks 2 and 3 following combination treatment and staining of
CD4þCD25þFoxp3þand CD4þFoxp3þHeliosþ Tregs, and Treg activation markers were carried out and
analyzed by ﬂow Cytometry (Fig. 4). In addition, total B cell (%; Fig. 5A), PCs (%; Fig. 5B) Transitional B
cells (%; Fig. 5C) and CXCR4þPCs (%; Fig. 5D) were investigated using ﬂow cytometry analysis. Fur-
thermore, a new combination treatment was administered into HemA inhibitor mice. Fig. 6 demon-
strates the combination treatment timeline for one cycle per every two weeks. The combination
treatment include IL-2/IL-2mAb complexes þ Anti-CD20þAMD3100þG-CSF. Inhibitor titers in FVIII
plasmid primed HemA mice with pre-existing inhibitors following combination treatment and control
HemA inhibitor mice over 16 weeks were shown in Fig. 7. A representative ﬁgure and gating strategies
Fig. 1. Single cycle of AMD3100 treatment reduced inhibitor titers in HemA inhibitor mice. HemA inhibitor mice were treated
with 200 μg/mouse/day for 10 days. Signiﬁcant reduction of titers were observed in treated mice (A; n¼3), compared to the
inhibitor only controls (B; n¼4). (C and D) showed B cells staining results. Total B (C) and PCs (D) were decreased in the
AMD3100 treated mice. Data shown is representative of two independent experiments.
Fig. 2. Single cycle of G-CSF treatment transiently reduced the inhibitor titers in HemA inhibitor mice. HemA inhibitor mice were
treated with G-CSF 250 μg/kg/day for 5-days. The inhibitory titers were transiently reduced in G-CSF treated mice (n¼3) (A), whereas
high levels of inhibitors titers persisted in inhibitor only control mice (n¼4) (B). B cell staining results showed that total B (C) and
CXCR4þ PCs (D) were slightly reduced after the G-CSF treatment. Data shown is representative of two independent experiments.
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Fig. 3. Inhibitor titers were reduced during the treatment with IL-2/IL-2mAb complexesþrapamycinþAMD3100 in FVIII-
plasmid treated HemA mice with pre-existing inhibitors. FVIII primed inhibitor mice (n¼8) were treated with IL-2/IL-2mAb
complexesþrapamycinþAMD3100 for 4 weeks. (A) The inhibitor titers were reduced during the treatment period and sus-
tained for 2 more weeks, however the titers returned to higher levels afterwards compared to persistently high levels of
inhibitor titers in the inhibitor only mice (n¼4) (B). Data shown is representative of two independent experiments.
Fig. 4. Effects of Immunomodulation on CD4þCD25þFoxp3þ and CD4þFoxp3þHeliosþ Tregs, and Treg activation markers in
peripheral blood in treated HemA inhibitor mice. PBMC were collected on weeks 2 and 3 after combination treatment (IL-2/IL-
2mAb complexesþrapamycinþAMD3100) in HemA inhibitor mice (n¼8), the percentage (%) of gated cells of
CD4þCD25þFoxp3þ Tregs (A) and Heliosþ Tregs (B) were investigated in each mouse group. MFI levels of Treg activation
markers CD25þ (C), GITRþ (D) and CTLA4þ (E) were also investigated at different time points after treatment. Data shown is
representative of two independent experiments.
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transitional B, PCs and CXCR4þPCs) in peripheral blood in treated HemA inhibitor mice was shown
(Fig. 8). Inhibitor titers in FVIII protein primed HemA mice with pre-existing inhibitors following
Fig. 5. Effect of immunomodulation on total and transitional B cells, PCs and CXCR4þ PCs in peripheral blood of each mouse
group (n¼8). PBMCs were collected and stained for B cell and PC populations at different time points following treatment.
(A) Total B cell (%), (B) PCs (%), (C) Transitional B cells (%) and (D) CXCR4þ PCs (%) were investigated using ﬂow cytometry
analysis. Data shown is representative of two independent experiments.
Fig. 6. The combination treatment timeline for one cycle per two weeks. The combined regimens were given as shown in the
timeline plotted. One cycle treatment includes two weeks long (14-days) period. For each cycle, IL-2/IL-2mAb complexes were
given on Mon, Tue and Wed every week, G-CSF was administered everyday for 6-days in the ﬁrst week, Anti-CD20 was given
3-days on Monday, Tuesday andWednesday in the ﬁrst week, and AMD3100 was administered everyday for 10-days within the
14-days treatment period.
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and results were described in Ref [1].
2. Experimental design, materials and methods
2.1. Mice
All mice were maintained at a speciﬁc pathogen-free (SPF) facility according to the National
Institutes of Health guidelines for animal care and the guidelines of Seattle Children's Research
Fig. 7. Inhibitor titers in FVIII plasmid primed HemA mice with pre-existing inhibitors following combination treatment. Two
groups of HemA mice were treated separately with different combination regimens 2-weeks per cycle for 3 cycles: (A) IL-2/IL-
2mAb complexesþanti-CD20þAMD3100þG-CSF (n¼4), (B) Inhibitor mice only (n¼4) as the control group. Peripheral blood
was collected at different time points following the combination treatment. Anti-FVIII antibody titers were assessed by
Bethesda assay over time. Each symbol represents data obtained from an individual mouse.
Fig. 8. Gating strategies on CD4þCD25þFoxp3þ , CD4þFoxp3þHeliosþ Tregs, and B cell populations (total B, transitional B, PCs
and CXCR4þPCs) in peripheral blood in treated HemA inhibitor mice. PBMCs were collected on indicated time points after
combination treatment (IL-2/IL-2mAb complexesþG-CSFþAMD3100þanti-CD20) in HemA inhibitor mice. (A) The percentage
(%) of gated cells of CD4þCD25þFoxp3þ Tregs and Heliosþ Tregs were investigated in each mouse group. (B) Total B cell (%),
PCs(%), transitional B cells (%) and CXCR4þ PCs (cell number) were gated using ﬂow cytometry analysis.
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8 weeks.2.2. Generation of HemA inhibitor mice
We generated HemA inhibitor mice by injecting HemA mice intravenously (i.v.) with 50 μg of FVIII
plasmid (pBS-HCRHPI-FVIIIA [2]) in 2 ml phosphate-buffered saline (PBS) via tail vein in 8–10 s, or
Fig. 9. Inhibitor titers in FVIII protein primed HemA mice with pre-existing inhibitors following combination treatment. Two
groups of HemA mice were treated separately with different combination regimens 2-weeks per cycle for 3 cycles: (A) IL-2/IL-
2mAb complexesþanti-CD20þAMD3100þG-CSF (n¼4), (B) Anti-CD20þAMD3100þG-CSF (n¼5), and (C) Inhibitor mice only
(n¼5) as the control group. Peripheral blood was collected at different time points following the combination treatment. Anti-
FVIII antibody titers were assessed by Bethesda assay over time. Each symbol represents data obtained from an individual
mouse. Data shown is representative of two independent experiments.
C.L. Liu et al. / Data in Brief 7 (2016) 973–980 979intraperitoneally (i.p.) with low dose FVIII protein (2U/mouse/wk; Kogenate
s
, Bayer (Whippany, NJ))
consecutively for 4 weeks.
2.3. Administration of single or combined immunomodulating agents into mice
Immunomodulation agents with indicated dosages were administered into mice according to
schedules speciﬁed in experiments. Blood samples were taken from the retro-orbital plexus at serial
time points.
2.4. Flow cytometry and antibodies
Cell suspensions of peripheral blood and spleens of each treated mouse group were prepared
according to standard protocols. Cell suspensions were stained for FACS analysis using appropriate
antibodies. Samples were analyzed on an LSRII ﬂow cytometer (Becton Dickinson, Palo Alto, CA) and
data were analyzed using FlowJo software (Tree Star, Ashland, OR).
2.5. FVIII activities and inhibitor titers assays
Peripheral blood samples were taken from the experimental mice and collected in a 3.8% sodium
citrate solution. FVIII activities were evaluated from the activated partial thromboplastin time (APTT)
by a modiﬁed clotting assay using FVIII deﬁcient plasma and reagents. FVIII activities were calculated
from a standard curve generated with serially diluted normal human pooled plasma. Anti-FVIII
antibody titers were measured by Bethesda assay.Acknowledgment
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